Search | Clinical Trials Finder

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol + Fluticasone Furoate, Placebo, Albuterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: HIV-associated Lipodystrophy Syndrome
Interventions: GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Asthma
Interventions: Fluticasone furoate, Matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 2,696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more

Conditions: Asthma
Interventions: Placebo ELLIPTA inhaler, Questionnaire; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more

Conditions: Myocardial Remodeling
Interventions: Eplerenone, Lactose Tablet; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acute Migraine With or Without Aura
Interventions: sumatriptan nasal powder, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more

Conditions: Influenza
Interventions: 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 70
States / cities: Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more

Conditions: Cardiogenic Shock
Interventions: Istaroxime, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: School Feeding Programs and Nutrition Supplements
Interventions: protein powder supplement, Vitamins/minerals; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 9 Years
Enrollment: 1,041 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate/Vilanterol, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Riverside, California • Sunset, Louisiana • Saint Charles, Missouri + 14 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adult Healthy Volunteers
Interventions: modified Handihaler DPI, standard Handihaler DPI; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Feeding Disorders, Specific Phobia
Interventions: Behavioral Intervention, d-cycloserine (DCS), Placebo; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Months to 6 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Asthma
Interventions: Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 19
States / cities: Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more

Conditions: Exercise-induced Bronchospasm
Interventions: arformoterol, formoterol, placebo; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Asthma
Interventions: Fp MDPI, FS MDPI, Advair Diskus, Albuterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 10
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more

Conditions: Exercise-Induced Bronchoconstriction (EIB)
Interventions: Albuterol Spiromax, Placebo Spiromax; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 6
States / cities: San Diego, California • Denver, Colorado • Wheaton, Maryland + 2 more

Conditions: Depression
Interventions: Herbal extract, Sertraline, Lactose monohydrate; Dietary Supplement · Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parainfluenza
Interventions: DAS181 dry powder, formulation F02, Lactose Placebo; Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 45
States / cities: Phoenix, Arizona • Duarte, California • Orange, California + 33 more

Conditions: Covid19, Anosmia, Olfactory Disorder, Covid-19 Pandemic, SARS-CoV-2 Infection, Hyposmia, Ageusia, Hypogeusia
Interventions: Theophylline Powder, Placebo Comparator; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate/Vilanterol, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Jasper, Alabama • Phoenix, Arizona • Fort Lauderdale, Florida + 14 more

Conditions: Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions: Budesonide, Saline alone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

Healthy and Affordable Protein Rich Foods for African Market

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques

D-cycloserine and Treatment of Feeding Disorders

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

Rhodiola Rosea Therapy of Major Depressive Disorder

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Smell in Covid-19 and Efficacy of Nasal Theophylline

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis